STOCK TITAN

AbCellera CFO exercises options for 50,000 shares

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Neutral)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
4

Rhea-AI Filing Summary

AbCellera Biologics Inc. Chief Financial Officer Andrew Booth exercised options to acquire 50,000 common shares on November 13, 2026, at $0.3216 per share, and donated 50,000 common shares to charity that day. He reported 130,959 common shares held indirectly by his spouse. No Rule 10b5-1 plan is reported.

Insider Booth Andrew
Role Chief Financial Officer
Type Security Shares Price Value
Exercise Share option (right to buy) F2 50,000 $0.00 $0.00
Exercise Common Shares 50,000 $0.3216 $16K
Gift Common Shares F1 50,000 $0.00 $0.00
Holding Common Shares -- -- --
Holdings After Transaction: Share option (right to buy) — 8,451,849 options (Direct); Common Shares — 491,400 shares (Direct); Common Shares — 130,959 shares (Indirect, By spouse)
Footnotes (2)
  1. F1. This transaction represents a charitable donation of 50,000 common shares the reporting person donated on November 13, 2026.
  2. F2. The shares subject to such option vest and become exercisable annually in substantially equal installments over a four-year period, with the first tranche vested on 22-Aug-2020, subject to the Reporting Person's continuous service to the Issuer on each such date.
Shares acquired on option exercise 50,000 common shares November 13, 2026
Option exercise price $0.3216 per share November 13, 2026 exercise
Shares donated to charity 50,000 common shares November 13, 2026
Shares following option exercise 8,451,849 shares Reported after the November 13, 2026 exercise
Indirect shares held by spouse 130,959 common shares Reported as of November 13, 2026
exercisable technical
"become exercisable annually in substantially equal installments"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What ABCL shares did CFO Andrew Booth exercise or donate?

Andrew Booth exercised options to acquire 50,000 common shares at $0.3216 per share and donated 50,000 common shares to charity on November 13, 2026. No Rule 10b5-1 plan is reported.

How many ABCL shares were held indirectly by Andrew Booth's spouse?

Andrew Booth reported 130,959 common shares held indirectly by his spouse as of November 13, 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Booth Andrew

(Last)(First)(Middle)
C/O ABCELLERA BIOLOGICS INC
150 W 4TH AVENUE

(Street)
VANCOUVER

(City)(State)(Zip)

BRITISH COLUMBIA, CANADA

(Country)
2. Issuer Name and Ticker or Trading Symbol
AbCellera Biologics Inc. [ ABCL ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
Chief Financial Officer
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
11/13/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Shares11/13/2026MV50,000A$0.3216541,400D
Common Shares11/13/2026GV50,000D$0(1)491,400D
Common Shares130,959IBy spouse
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Share option (right to buy)$0.321611/13/2026MV50,000 (2)08/22/2029Common Shares50,000$08,451,849D
Explanation of Responses:
1. This transaction represents a charitable donation of 50,000 common shares the reporting person donated on November 13, 2026.
2. The shares subject to such option vest and become exercisable annually in substantially equal installments over a four-year period, with the first tranche vested on 22-Aug-2020, subject to the Reporting Person's continuous service to the Issuer on each such date.
Remarks:
Tryn Stimart, attorney-in-fact11/13/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Keep reading